Cambridge Study Issues Stark Warning on Weight Regain After Stopping Obesity Jabs
Individuals who cease taking weight loss injections such as Mounjaro and Wegovy are at risk of regaining nearly two-thirds of the weight they initially shed, according to a comprehensive new study from the University of Cambridge. The research, which analysed data from over 3,200 participants across six clinical trials, highlights significant concerns about the long-term effectiveness of these popular GLP-1 receptor agonist medications when treatment is discontinued.
Rapid Weight Regain Observed Within First Year
The Cambridge scientists discovered that within 52 weeks of stopping the injections, participants regained an average of 60% of the weight they had lost during treatment. This substantial rebound effect underscores the challenges of maintaining weight loss without continued pharmaceutical intervention. The findings, published in the medical journal eClinicalMedicine, indicate that while some weight loss may be sustained long-term, the immediate post-treatment period presents significant risks for weight recovery.
Brajan Budini, a medical student at Cambridge's School of Clinical Medicine and Trinity College, explained the mechanism behind this phenomenon: "Drugs such as Ozempic and Wegovy act like brakes on our appetite, making us feel full sooner, which means we eat less and therefore lose weight. When people stop taking them, they are essentially taking their foot off the brake and this can lead to rapid weight regain."
Potential Health Risks from Body Composition Changes
Perhaps more concerning than the sheer weight regain is the potential change in body composition that may accompany it. Researchers caution that if the regained weight consists disproportionately of fat rather than lean muscle mass, individuals could find themselves "worse off than before" they began treatment. This shift in fat-to-lean mass ratio could have adverse consequences for metabolic health and overall wellbeing.
The study suggests that while weight regain begins to taper off around 60 weeks post-treatment, with patients maintaining approximately 25% of their original weight loss, the quality of that maintained weight remains uncertain. "Our projections show that even though people regain most of the weight they have lost, they still maintain some of the weight loss," Budini noted. "But what we currently don't know is if the same proportion of lean mass is recovered."
Current Prescribing Guidelines Deemed Inadequate
The Cambridge researchers have identified significant gaps in current prescribing practices and guidelines for GLP-1 receptor agonists. They note that existing protocols are "inconsistent and largely inadequate in addressing the risk of weight regain following treatment cessation." This lack of standardized guidance creates uncertainty for both healthcare providers and patients navigating obesity treatment.
For instance, while the National Institute for Health and Care Excellence recommends that patients take semaglutide (the active ingredient in Wegovy) for weight management for a maximum of two years, no such restriction exists for tirzepatide (Mounjaro). This inconsistency highlights the need for more comprehensive treatment frameworks.
Calls for Further Research and Improved Patient Support
Steven Luo, another medical student involved in the Cambridge research, emphasized the importance of holistic approaches to weight management: "When stopping weight loss drugs, doctors and patients should be aware of the potential for weight regain and consider ways to mitigate this risk. It's important that people are given advice on improving their diet and exercise, rather than relying solely on the drugs, as this may help them maintain good habits when they stop taking them."
The research team has called for additional studies to examine how GLP-1 receptor agonists affect body composition both during and after treatment. They stress that understanding these mechanisms is crucial for developing more effective long-term strategies for obesity management that don't create dependency on pharmaceutical interventions.
Both Mounjaro and Wegovy, which were originally developed for type 2 diabetes treatment before receiving NHS approval for obesity management, work by mimicking the GLP-1 hormone to regulate blood sugar and insulin levels while suppressing appetite. Their growing popularity has made understanding their long-term effects increasingly important for public health planning and individual patient care.
